Search the Newsreel

Babcock & Wilcox Signs Agreement with Siemens Energy to Commence Work on 20 Steam Turbines for Data Center Power Generation

- Agreement positions B&W to deliver 20 50-megawatt steam turbines for customers on accelerated timelines - AI data centers and large-scale power generation projects driving energy demand AKRON, Ohio, August 11, 2026--(BUSINESS WIRE)--Babcock & Wilcox (B&W) (NYSE: BW) announced today that it has signed …

Babcock & Wilcox Shares Surge 40.5% After Q2 Results Beat Expectations and Guidance Rises

Babcock & Wilcox Enterprises, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:BW) 2026-08-11

Babcock Q2 Earnings Call Highlights

Babcock & Wilcox earnings on deck as profitability in focus By Investing.com

Babcock & Wilcox targets $80M-$105M 2026 adjusted EBITDA amid $14B+ pipeline expansion

Earnings Call Insights: Babcock & Wilcox Enterprises (BW) Q2 2026 MANAGEMENT VIEW * “We are pleased to report another strong quarter, highlighted by robust financial results and active project development and continued operational momentum in our core business and further strategic debt reduction and …

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

AbCellera (Nasdaq: ABCL) is set to release top-line data from its Phase 2 trial of ABCL635 for moderate-to-severe vasomotor symptoms (VMS) due to menopause on Monday, August 10, 2026. The company will also host an investor conference call and webcast to discuss the results. …

Earnings call transcript: Babcock & Wilcox tops Q2 2026 estimates, shares jump

Babcock & Wilcow Enterprises (BW) Q2 Earnings and Revenues Surpass Estimates

AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook

AbCellera Biologics (ABCL) surged 44% to a three-year high following positive clinical trial results for its hot flash treatment, ABCL635. The drug significantly reduced hot flashes in postmenopausal women, outperforming a placebo, and analysts are bullish on its potential in a large addressable market. …

Babcock & Wilcox surges as revenue, earnings crush estimates (BW:NYSE)

Babcock & Wilcox Enterprises earnings beat by $0.04, revenue topped estimates

Babcock & Wilcox: Q2 Earnings Snapshot

Babcock & Wilcox (NYSE: BW) swings to Q2 profit, lifts 2026 EBITDA target

Babcock & Wilcox (NYSE: BW) reported a significant financial turnaround in Q2 2026, swinging to a net profit of $14.3 million from a loss of $58.5 million in the prior year, with revenue surging 130% to $319.7 million. The company raised its full-year 2026 …

Babcock & Wilcox (NYSE: BW) swings to Q2 profit on surging project revenue

AbCellera stock soars on ‘off the chart’ trial results from hot flash treatment for menopausal women

AbCellera Biologics Inc. saw its stock soar after announcing "off the chart" human trial results for its hot flash treatment, ABCL635, which proved more effective and had fewer side effects than existing therapies. The drug, aimed at menopausal women and those undergoing hormone-suppressing cancer …

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera has announced positive top-line results from its Phase 2 clinical trial for ABCL635, an investigational antibody for treating moderate-to-severe vasomotor symptoms (hot flashes) in menopausal women. The study demonstrated statistically significant reductions in both the frequency and severity of symptoms, as well as …

AbCellera Biologics Sees Unusually High Options Volume (NASDAQ:ABCL)

AbCellera Biologics (NASDAQ:ABCL) experienced unusually high options trading volume, with investors purchasing 16,666 call options, a 151% increase over the average. The company's shares surged by $2.37 to $9.30 on heavy trading volume, despite missing analyst expectations for both earnings and revenue in its …

Abcellera Biologics stock hits 52-week high at 8.79 USD

Abcellera Biologics Inc. (ABCL) reached a 52-week high of $8.79, reflecting a 63% total return over the past year and 119% over six months. Despite this, an InvestingPro analysis suggests the stock may be overvalued. The company also announced positive Phase 2 clinical trial …

Why is Abcellera Biologics stock surging today?

Abcellera Biologics (ABCL) stock surged over 30% in pre-open trading after its antibody, ABCL 635, met the primary efficacy endpoint in a Phase 2 clinical trial for menopausal hot flashes, showing an 83% reduction in frequency. This clinical success, combined with strong analyst conviction …

AbCellera's ABCL635 Delivers Strong Phase 2 Data; Stock Jumps 33%

(RTTNews) - AbCellera Biologics Inc. (ABCL) announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational NK3R antagonist antibody for moderate-to-severe vasomotor symptoms due to menopause. The study met its primary efficacy endpoints achieving statistically …

AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

AbCellera Biologics announced positive top-line results from its Phase II trial of ABCL-635, a non-hormonal treatment for menopausal hot flashes. The study showed an 83% reduction in moderate-to-severe hot flashes, along with improvements in symptom severity and sleep disturbance, and a favorable tolerability profile. …

ABCL Stock Rips As Vertex Deal And Data Catalyst Fire Up Traders

AbCellera Biologics Inc. (ABCL) stock surged over 24% due to strong optimism surrounding its antibody discovery platform, a new collaboration with Vertex Pharmaceuticals, and upcoming Phase 2 data for ABCL635. The Vertex deal provides $28 million upfront, with potential milestones and royalties, validating ABCL's …

AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Just Slashed This Year's Revenue Estimates By 22%

Analysts have significantly revised down AbCellera Biologics Inc.'s (NASDAQ:ABCL) revenue estimates for 2026 by 22%, now forecasting US$25 million, which represents a 62% decline year-over-year. Despite this pessimistic outlook, the company's share price has recently risen by 19%. The updated forecasts suggest AbCellera Biologics …

AbCellera To Present Phase 2 Results Of ABCL635 For Menopause Symptoms Today

(RTTNews) - AbCellera Biologics Inc. (ABCL) announced that it will release top-line results from its Phase 2 clinical trial from its Phase 2 clinical trial of ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes due to menopause, before …

AbCellera Biologics (ABCL) Is Up 21.4% After First Phase 2 Readout For Novel NK3R Antibody – Has The Bull Case Changed?

AbCellera Biologics (ABCL) saw its stock rise 21.4% following the first Phase 2 readout for its novel NK3R antibody, ABCL635, targeting menopausal vasomotor symptoms. This marks a significant step in AbCellera's shift towards developing internal therapeutic programs, offering an early test of its new …

AbCellera (NASDAQ:ABCL) Shares Surge Ahead of Monday's ABCL635 Phase 2 Trial Results

AbCellera's shares surged ahead of the release of its ABCL635 Phase 2 trial results on Monday, with the stock gaining 9.7% in after-hours trading, adding an estimated $205 million to its market value. Despite recent quarterly revenue declines, the anticipation of clinical validation for …

AbCellera Biologics | 8-K: Current report

This document is an 8-K current report filed by AbCellera Biologics. The content of the report itself is not provided, only the fact that it is an 8-K filing.

BABCOCK & WILCOX ENTERPRISES Q2 2026 Earnings Preview: Recent $BW Insider Trading, Hedge Fund Activity, and More

Banco ABC Brasil (ABCB4): resultado do 2T26, diversificação e perspectivas

AbCellera Biologics (ABCL) Stock Jumps As Cash Burn Fuels Pipeline Debate

AbCellera Biologics (ABCL) saw its stock jump 10.3% despite reporting a significant cash burn and widening net loss in Q2 2026. The market reaction is attributed to the company's substantial cash pile of US$567 million and over US$675 million in liquidity, which is being …

AbCellera Biologics Inc. $ABCL Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC significantly reduced its stake in AbCellera Biologics Inc. (NASDAQ:ABCL) by 36.8% in the first quarter, selling 878,600 shares but still retaining 1.51 million shares valued at $5.27 million. This comes as AbCellera reported weaker-than-expected quarterly results, missing both earnings per share …

AbCellera Biologics Inc. Stock 12‑Month Price Target Raised to $10.75, Implies 82% Upside

AbCellera Biologics Inc. (ABCL) has seen its average 12-month price target raised to $10.75 by 8 analysts, up from $10.50, with individual forecasts ranging from $7 to $13. This updated target suggests an 82% potential upside based on the August 5th closing price. The …

Earnings call transcript: AbCellera misses Q2 2026 estimates as revenue drops

AbCellera Biologics Inc. reported a wider-than-expected Q2 2026 loss and revenue significantly below analyst estimates, with revenue dropping by 76% year-over-year. The company attributed the revenue decline to a strategic shift from external collaborations to internal drug development, leading to increased R&D spending. Despite …

AbCellera Biologics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ABCL) 2026-08-06

This document is AbCellera Biologics' 10-Q filing for its Q2 2026 earnings report. A 10-Q is a comprehensive quarterly report filed by public companies with the SEC, containing unaudited financial performance. It provides a detailed overview of the company's financial condition and results of …

Stifel Nicolaus Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price